Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 9/20 | 0.51 |
| ▸ | RAB9A | P51151 | 9/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758308 | 0.85 | CYP1A2 (0.77) | CYP1A2LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL5660816 | 0.85 | CYP1A2 (1.00) | CYP1A2LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL759906 | 0.76 | CYP1A2 (0.59) | CYP1A2LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL5068803 | 0.74 | CYP1A2 (0.60) | CYP1A2LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL20556228 | 0.74 | CYP1A2 (0.42) | CYP1A2LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL12203769 | 0.73 | CYP1A2 (0.59) | CYP1A2LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL28614649 | 0.73 | CYP1A2 (0.59) | CYP1A2LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL237417 | 0.73 | CYP1A2 (0.55) | CYP1A2LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL13255470 | 0.73 | CYP1A2 (0.55) | CYP1A2LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL237019 | 0.73 | CYP1A2 (0.55) | CYP1A2LMNANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | CYP1A2 253/4885LMNA 4760/4885NPC1 972/4885 |
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | CYP1A2 375/4885LMNA 1672/4885NPC1 122/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | CYP1A2 375/4885LMNA 1672/4885NPC1 122/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | CYP1A2 362/4885LMNA 1504/4885NPC1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.